Elastofibroma Dorsi: Tek Merkez Deneyimi

Abstract

Amaç: Elastofibroma dorsi nedeniyle opere edilen hastalarımızda tanı, takip, cerrahi tedavi ve sonuçları konusundaki deneyimlerimizi ortaya koymayı amaçladık. Gereç ve Yöntem: Cerrahi rezeksiyon uygulanan elastofibroma dorsi tanılı 25 hastanın verileri retrospektif olarak incelendi. Yaş, cinsiyet, taraf, semptom, özgeçmiş, meslek, boyut, dren takip zamanı ve postoperatif komplikasyonlar analiz edildi. Hastalar ayrıca patoloji raporunda yer alan lezyon boyutlarının üçünün (en, boy, yükseklik) çarpımı sonucu elde edilen hacim baz alınarak, <200 cm3 (Grup 1) ve 200 cm3≤ (Grup 2) olarak 2 gruba ayrıldı. Bulgular: Ortalama yaş 54,62±7,02 idi. Yirmi bir hastanın 4’ü (%19) erkek, 17’si (%81) kadındı. On bir (%52,4) kişi ev hanımı, 6 (%28,6) kişi işçi idi, 4 (%19) kişi kol kuvveti gerektirmeyen meslek yapmaktaydı. Lezyon hacim artışı ile dren sonlandırma zamanı arasında istatistiksel olarak anlamlı olmayan (p=0,563, r=0,134) doğru orantı vardı. Hiçbir hastamızda nüks gözlenmedi. Hiçbir hastamızda ağrı dışında postoperatif komplikasyon gözlenmedi. Sonuç: Semptomatik elastofibroma dorsi olgularının tedavisinde total cerrahi rezeksiyon etkili ve yeterli bir tedavi yöntemidir.

Keywords

• Elastofibroma Dorsi
• Cerrahi Rezeksiyon
• Yumuşak Doku Tümörü

Elastofibroma Dorsi: Single Center Experience

Abstract

Objectives: We aimed to reveal our experience in diagnosis, follow-up, surgical treatment and results in our patients who were operated for elastofibroma dorsi. Materials and Methods: The data of 25 patients diagnosed with elastofibroma dorsi, who underwent surgical resection, were retrospectively evaluated. Age, gender, side, symptom, disease history, job, size, drain follow-up time and postoperative complications were analyzed. The patients were also divided into 2 groups as <200 cm3 (Group 1) and 200 cm3≤ (Group 2) based on the volume obtained by multiplying three (width, height, height) of the lesion sizes in the pathology report. Results: The mean age was 54.62±7.02 years. 4 (19%) of 21 patients were male, 17 (81%) were female. Eleven (52.4%) people were housewives, 6 (28.6%) people were workers, 4 (19%) people were doing professions not requiring manual force. There was a non-statistically significant (p=0.563,r=0.134) direct proportion between lesion volume increase and drain termination time. No recurrence was observed in any of our patients. No postoperative complications were observed in any of our patients, except pain. Conclusion: Total surgical resection is an effective and sufficient treatment method in the treatment of symptomatic cases of elastofibroma dorsi.

Keywords

• Elastofibroma Dorsi
• Surgical Resection
• Soft Tissue Tumor

References

1. 1. Yenigün BM, Yildiz O, Yüksel C, et al. Elastofibroma dorsi: 11 olgunun analizi ve literatürün gözden geçirilmesi [Elastofibroma dorsi: report of 11 cases analysis and review of the literature]. Tuberk Toraks. 2014;62:85-88.
2. 2. Kuzucuoğlu M. Göğüs Duvarının Nadir Görünen Tümörü; Elastofibroma Dorsi. Balıkesir Sağlık Bilimleri Dergisi. 2017;6:75-78.
3. 3. Köksel O, Özgülder A, Özer C, et al. Elastofibroma Dorsi: Olgu Sunumu. Türk Gö¤üs Kalp Damar Cerrahisi Dergisi. 2005;13:279-282.
4. 4. Deveci MA, Özbarlas HS, Erdoğan KE, et al. Elastofibroma dorsi: Clinical evaluation of 61 cases and review of the literature. Acta Orthop Traumatol Turc. 2017;51:7-11.
5. 5. Bartocci M, Dell’Atti C, Meacci E, et al. Clinical features, imaging findings, treatment aspects of elastofibroma dorsi and long-term outcomes after surgical resection. Eur Rev Med Pharmacol Sci. 2017;21:2061-2068.
6. 6. Criscione A, Palmucci S, Calvo D, et al. Elastofibroma dorsi and the thoracic surgeon: experience with 13 patients. Future Oncol. 2015;11(24 Suppl):47-50.
7. 7. Sahin M, Gul VO. Is it necessary to always resect elastofibroma dorsi? ANZ J Surg. 2020 Dec 1.
8. 8. Di Vito A, Scali E, Ferraro G, et al. Elastofibroma dorsi: a histochemical and immunohistochemical study. Eur J Histochem. 2015;59:2459.

9. 9. Tepe M, Polat MA, Calisir C, et al. Prevalence of elastofibroma dorsi on CT: Is it really an uncommon entity? Acta Orthop Traumatol Turc. 2019;53:195- 198.
10. 10. Yarıkkaya E, Sayılgan AT, Özcan D. Elastofibromda Tru-Cut Biyopsinin Rolü:5 Olgu. Haseki Tıp Bulteni. 2012;50:146-149.
11. 11. Oliva MS, Smimmo A, Vitiello R, et al. Elastofibroma dorsi: What’s new? Orthop Rev (Pavia). 2020;12(Suppl 1):8708.
12. 12. Scamporlino A, Ruggiero C, Aramini B, et al. Surgery for elastofibroma dorsi: optimizing the management of a benign tumor-an analysis of 70 cases. J Thorac Dis. 2020;12:1884-1894.
13. 13. Cinar BM, Akpinar S, Derincek A, et al. Elastofibroma dorsi: Nadir görülen bir omuz ağrisi nedeni [Elastofibroma dorsi: an unusual cause of shoulder pain]. Acta Orthop Traumatol Turc. 2009;43:431-435.
14. 14. Başaran C, Dönmez FY, Öztürk A, et al. Elastofibroma Dorsi’de MRG Bulguları. Fırat Tıp Dergisi. 2009;14:65-68.
15. 15. Tsubakimoto M, Yamashiro T, Tsuchiya N, et al. MRI findings and demographics of elastofibroma dorsi: assessment of diffusion-weighted imaging and contrast enhancement patterns. Acta Radiol. 2018;59:709- 715.
16. 16. Minarro JC, Urbano-Luque MT, López-Jordan A, et al. The comparison of measurement accuracy among three different imaging modalities in evaluating elastofibroma dorsi. An analysis of 52 cases. Int Orthop. 2015;39:1145-1149.
17. 17. Fang N, Wang YL, Zeng L, et al. Characteristics of elastofibroma dorsi on PET/CT imaging with (18)F-FDG. Clin Imaging. 2016;40:110-113.
18. 18. Ishiyama M, Vesselle H. 68Ga DOTATATE PET/CT Imaging of Elastofibroma Dorsi. Clin Nucl Med. 2018;43:154-155.
19. 19. Oporto M, Cepa F, Orta N, et al. Fibroelastic pseudotumor elastofibroma dorsi detected by 18F-FDG PET/CT scan and by postherapy radioiodine SPECT/CT. Rev Esp Med Nucl Imagen Mol. 2018;37:46-49.
20. 20. Keskin H. Nadir Görülen Elastofibroma Dorsi’de Klinik Deneyimimize Dayanarak Tanı Ve Tedavi Algoritması Oluşturulması. Bozok Tıp Derg. 2018;8:18-24.
21. 21. Nagano S, Yokouchi M, Setoyama T, et al. Elastofibroma dorsi: Surgical indications and complications of a rare soft tissue tumor. Mol Clin Oncol. 2014;2:421-424.